Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Dysport dose-ranging study in upper back myofascial pain syndrome
2004-001845-13Phase 2Completed
- Sponsor
- Ipsen
- Start
- Dec 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in chronic myofascial pain (CMP) (4 arms), sponsored by Ipsen. Primary endpoint: Change in overall pain of the day during activity from baseline to week 6. Started Dec 2004; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic myofascial pain (CMP)
Beyond the preview
Go deeper on 2004-001845-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001845-13.